Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.44 -0.5%	$9.80	$2.20 ▼ $12.78	$258.56M	-0.58	198,339 shs	27,790 shs
FSDDF FSD Pharma	$16.75 +2.4%	$22.39	$3.43 ▼ $68.66	$126.97M	N/A	11,100 shs	98,183 shs
LCTX Lineage Cell Therapeutics	$1.21 -0.8%	$1.04	$0.37 ▼ $1.31	$276.32M	1.66	1.90 million shs	730,305 shs
VOR Vor Biopharma	$2.01 +0.5%	$1.89	$0.13 ▼ $3.29	$254.63M	2.06	7.81 million shs	4.58 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-2.56%	-5.57%	-5.38%	+5.85%	+111.93%
FSDDF FSD Pharma	0.00%	+0.31%	-28.09%	+54.05%	+311.02%
LCTX Lineage Cell Therapeutics	-2.40%	+2.52%	+4.27%	+77.84%	+28.68%
VOR Vor Biopharma	-3.85%	-9.09%	-17.36%	+925.12%	+124.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.393 of 5 stars	3.4	5.0	0.0	0.0	2.5	2.5	0.6
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	2.4128 of 5 stars	3.5	1.0	0.0	0.0	1.8	3.3	0.6
VOR Vor Biopharma	1.8567 of 5 stars	3.3	0.0	0.0	0.0	0.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	56.25% Upside
FSDDF FSD Pharma	0.00	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.25	251.24% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	201.82% Upside

Current Analyst Ratings Breakdown

Latest FSDDF, VOR, LCTX, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
8/14/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/5/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/23/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/23/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$3.15 per share	N/A
FSDDF FSD Pharma	$70K	1,813.79	N/A	N/A	N/A	∞
LCTX Lineage Cell Therapeutics	$9.50M	29.09	N/A	N/A	$0.21 per share	5.76
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
FSDDF FSD Pharma	-$17.52M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-374.84%	-20.00%	-12.93%	11/13/2025 (Estimated)
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest FSDDF, VOR, LCTX, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	2.45	2.45
FSDDF FSD Pharma	N/A	1.81	1.60
LCTX Lineage Cell Therapeutics	N/A	4.08	4.08
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
FSDDF FSD Pharma	0.43%
LCTX Lineage Cell Therapeutics	62.47%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
FSDDF FSD Pharma	N/A
LCTX Lineage Cell Therapeutics	26.80%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
FSDDF FSD Pharma	10	7.58 million	N/A	Not Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

FSDDF, VOR, LCTX, and DBVT Headlines

Recent News About These Companies

Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 Shares

August 28 at 8:06 AM | insidertrades.com

Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint

August 28 at 6:58 AM | msn.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

August 27 at 8:00 AM | globenewswire.com

Vor Biopharma Inc. (NYSE:VOR) Receives $6.07 Average PT from Brokerages

August 27 at 2:55 AM | americanbankingnews.com

Vor Bio to Participate in Upcoming Investor Conferences

August 26 at 8:00 AM | globenewswire.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 26 at 2:25 AM | marketbeat.com

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2025 | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19, 2025 | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17, 2025 | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Vor Biopharma

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FSDDF, VOR, LCTX, and DBVT Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.46 -0.03 (-0.31%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

FSD Pharma OTCMKTS:FSDDF

$16.75 +0.40 (+2.45%)

As of 08/27/2025

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.21 -0.01 (-0.82%)

Closing price 04:10 PM Eastern

Extended Trading

$1.21 0.00 (0.00%)

As of 05:29 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Vor Biopharma NYSE:VOR

$2.01 +0.01 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 05:34 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time